Table 1.
Percentage of the prevalence of prescribed antibiotics amongst reviewed studies.
| Antibiotic | Frequency Amongst Included Studies | Percentage Amongst Reporting Studies (n = 38) (%) |
|---|---|---|
| Cephalosporin | ||
| Third generation cephalosporin | 14 | 36.8 |
| Fourth generation cephalosporin | 2 | 5.3 |
| Cephalosporin (unspecified) | 2 | 5.3 |
| Macrolides | ||
| Azithromycin | 13 | 34.2 |
| Macrolide (unspecified) | 2 | 5.3 |
| Penicillin and Penicillin β-lactamase inhibitor combinations | ||
| Piperacillin-tazobactam | 4 | 10.5 |
| Amoxicillin-clavulanate | 3 | 7.9 |
| Penicillin | 3 | 7.9 |
| Amoxicillin | 1 | 2.6 |
| Beta lactam-beta lactamase inhibitor | 1 | 2.6 |
| Carbapenems | ||
| Meropenem | 4 | 10.5 |
| Imipenem | 1 | 2.6 |
| Carbapenems (unspecified) | 4 | 10.5 |
| Quinolones | ||
| Fluoroquinolones | 3 | 7.9 |
| Quinolones | 2 | 5.3 |
| Moxifloxacin | 1 | 2.6 |
| Glycopeptide | ||
| Vancomycin | 2 | 5.3 |
| Folate pathway inhibitors | ||
| Trimethoprim-sulfonamide | 1 | 2.9 |
| Aminoglycosides | ||
| Aminoglycosides | 1 | 2.9 |
| Lincosamides | ||
| Clindamycin | 1 | 2.9 |
| Glycylcyclines | ||
| Tigecycline | 1 | 2.9 |
| Lipopeptides | ||
| Daptomycin | 1 | 2.9 |
| Others Antibiotic (unspecified) | 16 | 42.1 |